Bo R. Zhang

Huaihai West Road No.241
Huaihai, 200030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Modified Xiaoyao San Ameliorates Depression-Like Behaviors and Neuronal Necroptosis in a Mouse Model of Chronic Unpredictable Mild Stress.

Modified Xiaoyao San Ameliorates Depression-Like Behaviors and Neuronal Necroptosis in a Mouse Model of Chronic Unpredictable Mild Stress.

Journal: Journal of visualized experiments : JoVE

Published: August 22, 2026

The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.

The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.

Journal: Pharmacological research

Published: March 14, 2026

Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

Journal: Therapeutic advances in medical oncology

Published: January 13, 2026

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Journal: Nature communications

Published: November 28, 2025

(-)-Guaiol inhibits lung cancer via PPARG-dependent fatty acid oxidation.

(-)-Guaiol inhibits lung cancer via PPARG-dependent fatty acid oxidation.

Journal: Neoplasma

Published: November 11, 2025

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 05, 2025

Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.

Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.

Journal: BMC cancer

Published: September 02, 2025

Hyper-aware adaptive heuristic algorithms: A novel approach for seed selection in hypergraph-based diffusion.

Hyper-aware adaptive heuristic algorithms: A novel approach for seed selection in hypergraph-based diffusion.

Journal: Chaos (Woodbury, N.Y.)

Published: August 20, 2025

(-)-Guaiol Downregulates M2 Tumor-Associated Macrophage Polarization Through PPAR-γ Signaling to Suppress Lung Cancer.

(-)-Guaiol Downregulates M2 Tumor-Associated Macrophage Polarization Through PPAR-γ Signaling to Suppress Lung Cancer.

Journal: Biological procedures online

Published: April 17, 2025

Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study.

Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 06, 2025

Physicochemical Characterization and Oral Bioavailability of Curcumin-Phospholipid Complex Nanosuspensions Prepared Based on Microfluidic System.

Physicochemical Characterization and Oral Bioavailability of Curcumin-Phospholipid Complex Nanosuspensions Prepared Based on Microfluidic System.

Journal: Pharmaceutics

Published: March 02, 2025

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer.

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer.

Journal: Cell death & disease

Published: February 21, 2025

Showing 1-12 of 69

Last Updated: 09/26/2026